The mission of SWOG is to improve the practice of medicine in detecting, preventing, and treating cancer. The SWOG Cancer Control Research Base supports this mission through the development, conduct, analysis, and publication of clinical trials in cancer treatment, control and prevention as well as associated research. On average SWOG manages 50 on-going protocols and recruits 5-15,000 patients or subjects yearly to its trials. Under the direction of the Group Chair, the Associate Chair for Cancer Control and Prevention sets the scientific agenda for cancer control and prevention (CCP) within SWOG, which is implemented within five CCP committees;Prevention, Molecular Epidemiology, Cancer Survivorship, Symptom Management and Quality of Life, and Outcomes and Comparative Effectiveness. Often in partnership one of the eight SWOG disease oriented committees (Breast, Gastrointestinal, Genitourinary, Leukemia, Lung, Lymphoma, Melanoma, and Myeloma). The investigators within CCP develop and conduct research that is relevant, innovative and translatable. Additionally, SWOG manages and supports a large set of biorepositories and the infrastructure to provide these clinically annotated specimens to the research community at large. Further, SWOG will provide a unique resource to the research community through the development of a Cancer Comparative Effectiveness Research Center (CCERC) to provide facilitate the prioritization, design, implementation and translation of prospective comparative effectiveness trials within the NCI cooperative group network. The CCERC will become a model infrastructure within the NIH for leveraging burgeoning opportunities in comparative effectiveness research, including the new Patient Centered Outcomes Research Institute (PCORI) and commercial health insurer's movement towards coverage with evidence development funding models. The SWOG Research Base is partnered with 26 Community Clinical Oncology Programs (CCOP) or Minority Based CCOP and approximately 35% of its total accrual comes from the CCOP program. CCOP physicians play a leadership role within the group structure.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA037429-29S1
Application #
8735363
Study Section
Special Emphasis Panel (ZCA1-SRLB-B (J1))
Program Officer
Minasian, Lori M
Project Start
1983-09-30
Project End
2015-05-31
Budget Start
2013-08-16
Budget End
2014-05-31
Support Year
29
Fiscal Year
2013
Total Cost
$405,248
Indirect Cost
$6,500
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Murtola, Teemu J; Gurel, Bora; Umbehr, Martin et al. (2016) Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 25:463-9
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2016) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv :
Guertin, Kristin A; Grant, Rachael K; Arnold, Kathryn B et al. (2016) Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stress. Free Radic Biol Med 95:349-56
Travis, Ruth C; Appleby, Paul N; Martin, Richard M et al. (2016) A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. Cancer Res 76:2288-300
Ding, Xiuhua; Kryscio, Richard J; Turner, Joshua et al. (2016) Self-Reported Sleep Apnea and Dementia Risk: Findings from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Trial. J Am Geriatr Soc 64:2472-2478
Lara Jr, Primo N; Moon, James; Hesketh, Paul J et al. (2016) SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol 11:420-5
Goodman, Phyllis J; Tangen, Catherine M; Darke, Amy K et al. (2016) Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial. Trials 17:400
Winchester, Danyelle A; Gurel, Bora; Till, Cathee et al. (2016) Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial. Prostate 76:565-74
Chan, June M; Darke, Amy K; Penney, Kathryn L et al. (2016) Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiol Biomarkers Prev 25:1050-8
Rand, Kristin A; Rohland, Nadin; Tandon, Arti et al. (2016) Whole-exome sequencing of over 4100 men of African ancestry and prostate cancer risk. Hum Mol Genet 25:371-81

Showing the most recent 10 out of 346 publications